www.nextgensciences.com
September 13th 2006 NextGen Sciences Launches New Range of Pre - cast 2D Electrophoresis Gels Offering Exceptional Reproducibility and Ease of Use optigelTM set to become the Gold Standard in 2D gel electrophoresis NextGen Sciences, the Cambridge UK based “Gene to Protein” company today announces that it has launched a new range of optigelTM high performance, large format, pre - cast 2D gels available in a choice of gradients and supports. Developed for customers who require definitive separation performance and reproducibility, optigels are available with either standard or low fluorescing glass plates to allow compatibility with both traditional and fluorescent labelling systems. 2D gel electrophoresis has become an increasingly important tool for the analysis of complex multi-protein samples. The major drawback of this system, which precludes universal acceptance of this technique has been the variability seen between gels, even those manufactured on the same day in the laboratory. The introduction of the a2DEoptimizerTM from NextGen offered customers a way to solve variability issues but was only really economic where the laboratories were casting large numbers of gels. With the launch of its customisable gradient pre-cast optigels, NextGen has overcome these hurdles and can now make this invaluable analytical tool available to all laboratories large and small. Manufactured using NextGen Sciences proprietary a2DEoptimizerTM automated gel casting system, optigels offer unmatched gel to gel and batch to batch reproducibility combined with the improved performance benefits of acrylamide gradients and the convenience of a pre-cast gel. “The Company has identified a significant niche in the research market where reproducibility is key.” Commented Dr James Heffernan, CEO of NextGen “Where large numbers of gels are used it makes sense to buy the a2DEoptimizerTM in order to get the level of consistency and performance from 2D gel electrophoresis that is expected. However where small numbers of gel plates are required and accuracy and consistency is paramount, we can now offer all laboratories access to the best pre cast 2D gels available today” he added. Customers who require unique protein separation conditions can also take advantage of a custom - gradient design service, available with 48 hour turnaround and at no additional cost compared to a standard pre-cast gel. Orders for catalogue gels will be dispatched within 24 hours. Commenting further Dr Heffernan said. “Independent studies across multiple gels, separate casting instruments and on different days, with a wide range of protein markers have yielded an average CV (variability) of only 3.4% across all of the gels produced. This is a result only previously wished for in the 2D gel market. It can now be the norm, with optigels becoming the “Gold Standard” in 2D gel separations”. To help the customer choose the optimal gradient for their sample the Company has launched small trial kits containing different linear gradients. Once the customer has determined which gradient works best for them, they can order in bulk with the assurance of gel to gel comparability, or can still choose to use a completely customised gradient prepared by NextGen all for the same price. Further information on optigels can be obtained from the NextGen website www.nextegensciences.com or from the optigelTM Product Manager Dr Robert Mount on +44 (0) 1480 410 850 For further details please contact: Dr James G Heffernan CEO, NextGen Group PLC 01480 420 979 Mike Wort, Anna Dunphy MC Bio-Communications Limited 020 7744 7711 -ends- About NextGen Sciences NextGen Group PLC (LSE:NGG) is a provider of expert systems, services and reagents focused on enabling enhanced access to and understanding of the role of proteins in diagnosis and drug discovery. The expert systems are built out of NextGen’s understanding of biological sciences and combine robotics, advanced engineering and rules based software in systems that range from partial to fully automated. NextGen also uses its systems and instruments to provide fee-for-service products to the pharmaceutical and biotechnology industry as well as those in academic research. The commercial strategy, published at the time of the successful flotation on AIM in December 2005, was to rapidly create a significant North American presence in order to commercialize its range of products as well as introduce the ContractExpressTM fee for service product offering that was launched in late 2005. Further details relating to NextGen Group PLC and its products can be found at www.nextgensciences.com For further information, please contact Mike Wort or Anna Dunphy at MC Bio-Communications on 0207 744 7711 or email mike@mcbiocomms.co.uk / anna@mcbiocomms.co.uk
If you can’t open this electronic message, visit www.nextgensciences.com
about us>
© NextGen Sciences Ltd 2006, All rights reserved If this information is not of interest to you, and you no longer wish to receive press releases, we apologise for any inconvenience caused. To be removed from further emails please click here